Sera Prognostics (SERA) Stock Analysis & Winston Score
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restric
Winston Score: 18/100 — Weak
Weak fundamentals across most pillars.
- Quality: Weak (1/30)
- Growth: Weak (1/20)
- Cash Flow: Weak (0/10)
- Stability: Good (5/10)
- Valuation: Data not available (0/10)
- Ownership: Good (10/15)
Key Facts
Price: $2.05
Market Cap: $78M
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Exchange: NASDAQ
